Topic:

R&D

Latest Headlines

Latest Headlines

PPD pairs off with Sellas to pick up the pipeline pace

PPD has signed a master service agreement with Swiss biotech Sellas, lending its drug development expertise to the company's efforts to advance a portfolio of treatments.

Blaze wins NCI funding for 'tumor paint' after successful dog study

Blaze Bioscience has nabbed a $1.5 million Small Business Innovation Research (SBIR) Phase II award from the National Cancer Institute (NCI) to continue researching its product, called Tumor Paint BLZ-100, which will be studied in people with soft tissue sarcoma. The company was awarded the funding based on the successful completion of a trial in 27 pet dogs with various tumor types.

Five questions for Aratana CEO Steven St. Peter

It's been a productive couple of weeks for Aratana Therapeutics. I had the opportunity to sit down with Aratana CEO Steven St. Peter last week to chat about recent developments, and more generally, the prospects for the animal health industry going forward. Here are some excerpts from our conversation.

Canadian government funds Elanco genomics project

The Canadian government is pouring $56 million into 12 projects aimed at translating genomic discoveries into marketable products, including several in the animal health industry. The initiative aims to link up academic institutions with users of genomic research, including drug companies, nonprofit agencies, and government bodies.

Nexvet starts pivotal trial of pain-relieving antibody for arthritic dogs

Dublin-based Nexvet Biopharma has become the first company to launch a pivotal clinical trial of a monoclonal antibody (mAb) designed to combat pain in dogs with osteoarthritis.

Merck and Roche prep breast cancer data for promising immunotherapy drugs

As fervor surrounding a new class of cancer drugs builds, drug giants Merck and Roche are set to roll out new data for their opposing immunotherapy drugs for breast cancer by the end of the year.

Adaptimmune's novel cancer treatment posts promising early results

Adaptimmune's pioneering approach to cancer immunotherapy has charted some impressive results in a small study. And while the biotech is quick to point out that it's early days yet, the data underscore the potential of a therapy that has convinced GlaxoSmithKline to bet up to $350 million on its future.

Stanford using ultrasound to power wireless 'smart chip' implant

Stanford seems to have found a niche in tiny wireless implants. In the latest development, the university announced that it is developing methods of beaming ultrasound to power implanted "smart chips" for the treatment of conditions like Parkinson's disease.

Moderna teams up with Karolinska to flesh out its mRNA promise

Well-funded biotech Moderna Therapeutics has inked a long-term deal with Sweden's Karolinska Institutet to spotlight new applications for the company's messenger RNA technology.

Agilent axes 300 employees to focus on applied markets and diagnostics businesses

Agilent Technologies is closing its nuclear magnetic resonance business, as the downsizing of its research products division continues. The move is expected to cost 300 jobs over the next 12 months in Santa Clara, CA, and Yarnton, England.